ATE297730T1 - Nasenspray enthaltend ondansetron-hydrochlorid - Google Patents

Nasenspray enthaltend ondansetron-hydrochlorid

Info

Publication number: ATE297730T1
Authority: AT; Austria
Prior art keywords: weight; antiemetic; ondansetron hydrochloride; cyclodextrin; beta
Prior art date: 2001-04-20

Application number

AT02252717T

Other languages

English (en)

Inventor

Jin Auh

Chang Hwan Kim

In Koo Chun

Original Assignee

Ahn Gook Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-20

Filing date

2002-04-17

Publication date

2005-07-15

2002-01-11 Priority claimed from KR10-2002-0001758A external-priority patent/KR100434390B1/ko

2002-04-17 Application filed by Ahn Gook Pharma Co Ltd filed Critical Ahn Gook Pharma Co Ltd

2005-07-15 Application granted granted Critical

2005-07-15 Publication of ATE297730T1 publication Critical patent/ATE297730T1/de

Links

MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical compound Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 title abstract 3
229960000770 ondansetron hydrochloride Drugs 0.000 title abstract 3
239000007921 spray Substances 0.000 title 1
230000003474 anti-emetic effect Effects 0.000 abstract 3
239000002111 antiemetic agent Substances 0.000 abstract 3
239000004480 active ingredient Substances 0.000 abstract 2
239000000463 material Substances 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
229920000858 Cyclodextrin Polymers 0.000 abstract 1
239000001116 FEMA 4028 Substances 0.000 abstract 1
239000002202 Polyethylene glycol Substances 0.000 abstract 1
229960000686 benzalkonium chloride Drugs 0.000 abstract 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract 1
235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
229960004853 betadex Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000007922 nasal spray Substances 0.000 abstract 1
229940097496 nasal spray Drugs 0.000 abstract 1
229920001223 polyethylene glycol Polymers 0.000 abstract 1
159000000000 sodium salts Chemical class 0.000 abstract 1
239000002904 solvent Substances 0.000 abstract 1
229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 abstract 1
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Otolaryngology (AREA)
Inorganic Chemistry (AREA)
Hospice & Palliative Care (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT02252717T 2001-04-20 2002-04-17 Nasenspray enthaltend ondansetron-hydrochlorid ATE297730T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20010021573		2001-04-20
KR10-2002-0001758A KR100434390B1 (ko)	2001-04-20	2002-01-11	1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1ｈ-이미다졸-1-일)메틸]-4ｈ-카바졸-4-온을 유효성분으로 하는 비강분무용조성물

Publications (1)

Publication Number	Publication Date
ATE297730T1 true ATE297730T1 (de)	2005-07-15

Family

ID=36217590

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02252717T ATE297730T1 (de)	2001-04-20	2002-04-17	Nasenspray enthaltend ondansetron-hydrochlorid

Country Status (6)

Country	Link
US (1)	US20030044356A1 (de)
EP (1)	EP1250925B1 (de)
JP (1)	JP4152118B2 (de)
AT (1)	ATE297730T1 (de)
DE (1)	DE60204620T2 (de)
ES (1)	ES2244726T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0328186D0 (en) *	2003-12-05	2004-01-07	West Pharm Serv Drug Res Ltd	Intranasal compositions
GB0329918D0 (en) *	2003-12-24	2004-01-28	West Pharm Serv Drug Res Ltd	Intranasal compositions
US20060045850A1 (en) *	2004-08-30	2006-03-02	Qpharma, Llc	Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
SG177217A1 (en) *	2007-01-17	2012-01-30	Devirex Ag	Cyclodextrin formulations
US20130213393A1 (en)	2009-12-22	2013-08-22	Evoke Pharma, Inc.	Nasal formulations of metoclopramide
ES2664599T3 (es) *	2009-05-20	2018-04-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antagonistas del receptor 5-HT3 de serotonina para uso en el tratamiento de trastornos vestibulares lesionales
US20110207764A1 (en) *	2010-02-23	2011-08-25	Valery Alakhov	Cyclopolysaccharide compositions
US20110288115A1 (en) *	2010-05-24	2011-11-24	Avmedis Llc	Treatment of vagally-mediated spectrum disorders
US8383663B2 (en)	2010-07-19	2013-02-26	Supratek Pharma Inc.	Bendamustine anionic-catioinic cyclopolysaccharide compositions
PT2747561T (pt) *	2011-08-25	2018-09-28	Evoke Pharma Inc	Tratamento de sintomas associados com a gastroparesia feminina
DE202013000748U1 (de)	2013-01-24	2013-02-19	Merz Pharma Gmbh & Co. Kgaa	Sprühbare flüssige Zubereitung zur insbesondere nasalen Anwendung mit erhöhter lokaler Verweilzeit
DE102013001151A1 (de)	2013-01-24	2014-07-24	Merz Pharma Gmbh & Co. Kgaa	Sprühbare flüssige Zubereitung zur insbesondere nasalen Anwendung mit erhöhter lokaler Verweilzeit
EP2759290B1 (de)	2013-01-24	2019-11-06	Merz Pharma GmbH & Co. KGaA	Sprühbare flüssige zubereitung zur nasalen anwendung mit erhöhter lokaler verweilzeit
US9050325B2 (en) *	2013-04-08	2015-06-09	Abdul Zahir	Ondansetron nasal spray composition
WO2015198350A1 (en) *	2014-06-25	2015-12-30	Synergia Bio Sciences Private Limited	A pharmaceutical oil-in-water nano-emulsion
WO2016118540A1 (en) *	2015-01-20	2016-07-28	Xoc Pharmaceuticals, Inc.	Treating and/or preventing emesis and/or nausea including acute and/or delayed nausea and/or emesis
HRP20240453T1 (hr)	2016-04-14	2024-06-21	Sensorion	(+)-azasetron za uporabu u liječenju poremećaja uha
US11517545B2 (en)	2016-12-15	2022-12-06	Evoke Pharma, Inc.	Treatment of moderate and severe gastroparesis
CN113559277B (zh) *	2018-01-11	2023-11-17	比卡生物科技（广州）有限公司	一种注射用卡巴他赛组合物及其制备方法
EP3827822B1 (de)	2018-07-25	2024-11-06	Bika Biotechnology (Guangzhou) Co., Ltd.	Docetaxelzusammensetzung zur injektion und herstellungsverfahren dafür
GB202301322D0 (en)	2023-01-30	2023-03-15	Therakind Ltd	Antiemetic pharmaceutical compositions for nasal delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU895334D0 (en) *	1986-07-30	1990-01-28	Sandoz Ag	Process for the preparation of nasal pharmaceutical compositions
GB9202464D0 (en) *	1992-02-05	1992-03-18	Danbiosyst Uk	Composition for nasal administration
US5897858A (en) *	1994-02-03	1999-04-27	Schering-Plough Healthcare Products, Inc.	Nasal spray compositions exhibiting increased retention in the nasal cavity
US5576311A (en) *	1994-11-30	1996-11-19	Pharmos Corporation	Cyclodextrins as suspending agents for pharmaceutical suspensions
US5688955A (en) *	1996-03-08	1997-11-18	Adolor Corporation	Kappa agonist compounds and pharmaceutical formulations thereof
US20030095927A1 (en) *	1997-10-01	2003-05-22	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
WO2000051582A2 (en) *	1999-03-01	2000-09-08	Sepracor Inc.	Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
WO2000074651A1 (de) *	1999-06-02	2000-12-14	Hexal Ag	Pharmazeutische zusammensetzung zur nasalen anwendung von wasserunlöslichen und/oder schwer wasserlöslichen wirkstoffen
US6780825B2 (en) *	2001-02-06	2004-08-24	Playtex Products, Inc.	Cleansing compositions with milk protein and aromatherapy

2002
- 2002-04-02 US US10/114,691 patent/US20030044356A1/en not_active Abandoned
- 2002-04-09 JP JP2002106961A patent/JP4152118B2/ja not_active Expired - Fee Related
- 2002-04-17 DE DE60204620T patent/DE60204620T2/de not_active Expired - Lifetime
- 2002-04-17 EP EP02252717A patent/EP1250925B1/de not_active Expired - Lifetime
- 2002-04-17 ES ES02252717T patent/ES2244726T3/es not_active Expired - Lifetime
- 2002-04-17 AT AT02252717T patent/ATE297730T1/de active

Also Published As

Publication number	Publication date
EP1250925B1 (de)	2005-06-15
JP2002356424A (ja)	2002-12-13
DE60204620T2 (de)	2006-05-11
EP1250925A2 (de)	2002-10-23
US20030044356A1 (en)	2003-03-06
DE60204620D1 (de)	2005-07-21
EP1250925A3 (de)	2003-11-26
JP4152118B2 (ja)	2008-09-17
ES2244726T3 (es)	2005-12-16

Legal Events

Date

Code

Title

Description

2006-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1250925

Country of ref document: EP

Publication	Publication Date	Title
DE60204620D1 (de)	2005-07-21	Nasenspray enthaltend Ondansetron-hydrochlorid
BR0003364A (pt)	2001-09-18	Composições farmacêuticas
CY1106522T1 (el)	2012-01-25	Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
ATE234634T1 (de)	2003-04-15	Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff
CY1107850T1 (el)	2013-06-19	Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
ES2193208T3 (es)	2003-11-01	Nuevos derivados de quinuclidina y composicion farmaceutica que los contiene.
IS8502A (is)	2006-06-08	Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
MXPA04000226A (es)	2004-05-21	Composiciones generadoras de mousse que contienen agentes de amonio cuaternario.
EA200400432A1 (ru)	2004-12-30	Производные мочевины
IS2310B (is)	2007-11-15	Nefholssamsetning úr rótigótíni
NO2010023I2 (no)	2011-10-17	Vernakalant eller et solvat eller farmasøytisk akseptabelt salt derav, herunder inkludert vernakalanthydroklorid
ATE271383T1 (de)	2004-08-15	Pulverformulierung zur inhalation
ATE376423T1 (de)	2007-11-15	Gelierende wässrige pharmazeutische zusammensetzungen
DE69635996D1 (de)	2006-05-18	Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
SE0402762D0 (sv)	2004-11-11	Indazole sulphonamide derivatives
PT1230236E (pt)	2005-03-31	Composto com propriedades de libertacao de hormonas de crescimento
BR0212075A (pt)	2004-09-28	Combinações de substâncias ativas fungicidas
JP3846537B2 (ja)	2006-11-15	コンタクトレンズ用装着液
BR0013793A (pt)	2002-05-14	Medicamentos profiláticos e terapêuticos para doenças oftálmicas
PT992509E (pt)	2004-12-31	Novos derivados macrolidos
TW200501963A (en)	2005-01-16	Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
ATE273704T1 (de)	2004-09-15	Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
AU2002344454A1 (en)	2004-06-07	Percutaneous absorption preparations containing 3-methyl-1-phenyl-2-pyrazolin-5-one
JP5092138B2 (ja)	2012-12-05	コンタクトレンズ装着液
HU0102987D0 (en)	2001-09-28	Pharmaceutical composition for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient